AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34760706 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Surgery (SILS)
Number of subjects: 200
Study 34760706 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laparoscopic Surgery (CLS)
Number of subjects: 200
Study 36169717 — intervention group
Group type: EXPERIMENTAL
Intervention: One-point flow cytometric MRD measurement at end of induction (EOI) with a threshold of 0.01%
Number of subjects: 227
Study 36169717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters and one-point MRD measurement
Number of subjects: 227
Study 36412168 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-zero ambulation (walking on the same day as the operation)
Number of subjects: 36
Study 36412168 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative physiotherapy (control group)
Number of subjects: 36
Study 34088338 — intervention group
Group type: EXPERIMENTAL
Intervention: Credelio Plus® (lotilaner and milbemycin oxime) administered orally at a dose rate of 20.0-41.5 mg/kg bodyweight once every 4 weeks for 3 months
Number of subjects: 419
Study 34088338 — intervention group
Group type: COMPARATOR
Intervention: Nexgard Spectra® (control product) administered as recommended once every 4 weeks for 3 months
Number of subjects: 419
Study 34088338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Credelio Plus® and Nexgard Spectra®)
Number of subjects: 419
Study 35689282 — intervention group
Group type: EXPERIMENTAL
Intervention: InterTan nail
Number of subjects: 18
Study 35689282 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck system (FNS)
Number of subjects: 18
Study 35689282 — intervention group
Group type: COMPARATOR
Intervention: Three cannulated screws
Number of subjects: 18
Study 35075359 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training group (PG); n=20
Number of subjects: 40
Study 35075359 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific sensory stimulation (control group [CG]); n=20
Number of subjects: 40
Study 34743149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on clinicopathologic variables (including ER+, PR+, HER2+ with Herceptin treatment, low ALNR) for predicting overall survival (OS)
Number of subjects: 345
Study 34743149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting OS
Number of subjects: 345
Study 32517663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccination (3 injections)
Number of subjects: 750
Study 32517663 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (NaCL 0.9%)
Number of subjects: 750
Study 34988724 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor exercise
Number of subjects: 120
Study 34988724 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor exercise
Number of subjects: 120
Study 34988724 — intervention group
Group type: COMPARATOR
Intervention: Untrained
Number of subjects: 120
Study 34153136 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based Cognitive Behaviour Therapy (T-CBT)
Number of subjects: 78
Study 34153136 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual Cognitive Behaviour Therapy (TAU-CBT)
Number of subjects: 78
Study 32668111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose followed by 90 mg twice daily) plus Aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily)
Number of subjects: 11016
Study 32668111 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily)
Number of subjects: 11016
Study 32668111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 11016
Study 32668111 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 11016
Study 35473729 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone for 1 week
Number of subjects: 24
Study 35473729 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone for 1 week
Number of subjects: 24
Study 35473729 — intervention group
Group type: COMPARATOR
Intervention: 1.125 mg dexamethasone per day for 1 week
Number of subjects: 24
Study 35473729 — intervention group
Group type: COMPARATOR
Intervention: 4.5 mg dexamethasone per day for 1 week
Number of subjects: 24
Study 33856860 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (5 d/wk, 20 min/d, 100 min/wk)
Number of subjects: 37
Study 33856860 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 37
Study 33856860 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise volume <100 min/wk
Number of subjects: 37
Study 33856860 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise volume ≥160 min/wk
Number of subjects: 37
Study 33856860 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater exercise volume
Number of subjects: 37
Study 33436279 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational video about lung cancer screening (LCS)
Number of subjects: 1281
Study 33436279 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1281
Study 32541874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pavlik harness
Number of subjects: 104
Study 32541874 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 104
Study 32541874 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (acetabular index at age 10 months)
Number of subjects: 104
Study 32541874 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (walking age)
Number of subjects: 104
Study 34978862 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational population
Number of subjects: 137933
Study 34978862 — intervention group
Group type: COMPARATOR
Intervention: Randomized population
Number of subjects: 137933
Study 34978862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk adjustment
Number of subjects: 137933
Study 34978862 — intervention group
Group type: EXPERIMENTAL
Intervention: Further adjustment for social factors
Number of subjects: 137933
Study 33477108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) (3 × 3 min at 10°C)
Number of subjects: 21
Study 33477108 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS) (9 × 30‐s carpal extension)
Number of subjects: 21
Study 33477108 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study 34951029 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive diary intervention (writing down three good things each day)
Number of subjects: 0
Study 34951029 — intervention group
Group type: COMPARATOR
Intervention: Control group (keeping a record of each meal for 4 weeks)
Number of subjects: 0
Study 32370640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score-integrated composite likelihood approach (PSCL)
Number of subjects: 0
Study 32370640 — intervention group
Group type: COMPARATOR
Intervention: Real-world data (RWD) patients treated with the same therapy as the control arm
Number of subjects: 0
Study 34560687 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic mechanical power calculated using the power equation adjusted by the respiratory system compliance (CRS)
Number of subjects: 1156
Study 32107315 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified complex decongestive physiotherapy
Number of subjects: 120
Study 32107315 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education program)
Number of subjects: 120
Study 34176749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral transcutaneous electrical nerve stimulation
Number of subjects: 86
Study 34176749 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 86
Study 33487192 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 per cent diluted vinegar
Number of subjects: 24
Study 33487192 — intervention group
Group type: COMPARATOR
Intervention: 1 per cent chloramphenicol
Number of subjects: 24
Study 33121883 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model
Number of subjects: 20716
Study 33121883 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 20716
Study 33121883 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 20716
Study 33121883 — intervention group
Group type: COMPARATOR
Intervention: Machine learning models (random forest, XGBoost, logistic regression)
Number of subjects: 20716
Study 35861265 — intervention group
Group type: EXPERIMENTAL
Intervention: EAB modification (EABM)
Number of subjects: 90
Study 35861265 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 90
Study 33731270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lefamulin 600 mg every 12 h for 5 days
Number of subjects: 368
Study 33731270 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin 400 mg every 24 h for 7 days
Number of subjects: 368
Study 33171645 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS consumption (aspartame)
Number of subjects: 101
Study 33171645 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS consumption (total NNS)
Number of subjects: 101
Study 33171645 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and BMI changes
Number of subjects: 101
Study 33171645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soda consumption
Number of subjects: 101
Study 33171645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose and saccharin intake
Number of subjects: 101
Study 35362417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cancer care plus early integrated palliative care
Number of subjects: 98
Study 35362417 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer care
Number of subjects: 98
Study 34512011 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 62
Study 34512011 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and multi-modal analgesia (Control Group G)
Number of subjects: 62
Study 34352596 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on sleep-disorder-related points
Number of subjects: 42
Study 34352596 — intervention group
Group type: COMPARATOR
Intervention: Sham control (auricular acupressure on sleep-disorder-unrelated points)
Number of subjects: 42
Study 33143507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 53
Study 33143507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorapatite (FA)
Number of subjects: 53
Study 33143507 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated Mallory‐Head Porous stem
Number of subjects: 53
Study 33884659 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 62
Study 33884659 — intervention group
Group type: COMPARATOR
Intervention: GnRHa buserelin
Number of subjects: 62
Study 33884659 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine oedema and full acceptance of the teaser stallion
Number of subjects: 62
Study 34190182 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-reablement program for 6 weeks
Number of subjects: 26
Study 34190182 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation in the hospital
Number of subjects: 26
Study 35941932 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS (atDCS)
Number of subjects: 32
Study 35941932 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral tDCS (bi-tDCS)
Number of subjects: 32
Study 35941932 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal tDCS (ctDCS)
Number of subjects: 32
Study 35941932 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 32
Study 33655587 — intervention group
Group type: EXPERIMENTAL
Intervention: Common cold
Number of subjects: 0
Study 33655587 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 0
Study 33655587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine acute upper RTIs (9-AURTIs)
Number of subjects: 0
Study 33655587 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RTIs
Number of subjects: 0
Study 33655587 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic, behavioral, and environmental factors
Number of subjects: 0
Study 32217500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Interactive Supervised Therapy (MIST)
Number of subjects: 40
Study 32217500 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study 34561939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis Dementia Risk Score (DDRS)
Number of subjects: 32288
Study 34561939 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of DDRS
Number of subjects: 32288
Study 34291484 — intervention group
Group type: EXPERIMENTAL
Intervention: LVA guided ablation in addition to pulmonary vein isolation (PVI)
Number of subjects: 340
Study 34291484 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 340
Study 34291484 — intervention group
Group type: EXPERIMENTAL
Intervention: LVA guided ablation in addition to PVI
Number of subjects: 340
Study 32809152 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medical management (medical treatment based on anticoagulation, delayed by 24 hours if intravenous thrombolysis was performed)
Number of subjects: 56
Study 32809152 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medical management
Number of subjects: 56
Study 35306197 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS model plus standard patient education (PE)
Number of subjects: 40
Study 35306197 — intervention group
Group type: COMPARATOR
Intervention: Standard patient education (PE) alone
Number of subjects: 40
Study 34213495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-dissolved alkaline electrolyzed water (AEW)
Number of subjects: 0
Study 34213495 — intervention group
Group type: COMPARATOR
Intervention: Purified tap water
Number of subjects: 0
Study 32997816 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blade scalpel (DBS)
Number of subjects: 21
Study 32997816 — intervention group
Group type: EXPERIMENTAL
Intervention: De‐epithelialized (DE) SCTG
Number of subjects: 21
Study 32997816 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (DBS and DE)
Number of subjects: 21
Study 36111547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Club (AC) - community health worker-led groups of 20-30 patients with ART dispensing at a community venue
Number of subjects: 409
Study 36111547 — intervention group
Group type: COMPARATOR
Intervention: Routine PHC clinics - local standard of care with nurse/doctor-led services
Number of subjects: 409
Study 32603526 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (1 mg/kg)
Number of subjects: 17
Study 32603526 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (2 mg/kg)
Number of subjects: 17
Study 32603526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 34351401 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 136
Study 34351401 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 136
Study 32424821 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Integrated Program (VIP) - a 6-week intensive, tailored, educational program including motivational interviewing, smoking cessation program, dietary and physical activity counseling, and patient education.
Number of subjects: 212
Study 32424821 — intervention group
Group type: COMPARATOR
Intervention: Control group (addiction care as usual)
Number of subjects: 212
Study 34032530 — intervention group
Group type: EXPERIMENTAL
Intervention: USRPT
Number of subjects: 14
Study 34032530 — intervention group
Group type: COMPARATOR
Intervention: RPT
Number of subjects: 14
Study 33545710 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-optimized radiotherapy (OORT)
Number of subjects: 10
Study 33545710 — intervention group
Group type: COMPARATOR
Intervention: Dose-optimized radiotherapy (DORT)
Number of subjects: 10
Study 33471202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZLB00 IOL
Number of subjects: 35
Study 33471202 — intervention group
Group type: COMPARATOR
Intervention: Diffractiva IOL
Number of subjects: 35
Study 33049927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics educational program
Number of subjects: 74
Study 35913014 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward‐back Spanish translation
Number of subjects: 380
Study 35913014 — intervention group
Group type: COMPARATOR
Intervention: Rigorous translation with cultural adaptation
Number of subjects: 380
Study 32941265 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for ruptured AVMs
Number of subjects: 0
Study 32941265 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of unruptured AVMs
Number of subjects: 0
Study 32941265 — intervention group
Group type: COMPARATOR
Intervention: ARUBA trial
Number of subjects: 0
Study 34906127 — intervention group
Group type: EXPERIMENTAL
Intervention: The Real Cost Smokeless campaign
Number of subjects: 2200
Study 34906127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2200
Study 34906127 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (including treatment and control)
Number of subjects: 2200
Study 32509046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided inactivation of myofascial trigger points (MTrPs) with dry needling, followed by wet needling and muscle fascia stripping by liquid knife in PL group.
Number of subjects: 132
Study 32509046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided inactivation of MTrPs with dry needling, followed by wet needling and muscle fascia stripping by liquid knife in PA group.
Number of subjects: 132
Study 32509046 — intervention group
Group type: COMPARATOR
Intervention: Routine oral drugs and weekly paraspinal nerve block in C1 group.
Number of subjects: 132
Study 32509046 — intervention group
Group type: COMPARATOR
Intervention: Routine oral drugs and weekly paraspinal nerve block in C2 group.
Number of subjects: 132
Study 34542001 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐layer rack group (MULTI)
Number of subjects: 0
Study 34542001 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐touch pole clamp group (ONE)
Number of subjects: 0
Study 34542001 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study 33518062 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR) 250 mg/kg
Number of subjects: 360
Study 33518062 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic positive control (200 mg/kg oxytetracycline calcium and 250 mg/kg nasiheptide)
Number of subjects: 360
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Original prediction model for POAG development (C statistic = 0.741)
Number of subjects: 1106
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP
Number of subjects: 1106
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum IOP
Number of subjects: 1106
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: SD of IOP
Number of subjects: 1106
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of IOP
Number of subjects: 1106
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation IOP
Number of subjects: 1106
Study 32496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including mean follow-up IOP, age, central corneal thickness, vertical cup-disc ratio, and pattern SD
Number of subjects: 1106
Study 32496526 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from EGPS
Number of subjects: 1106
Study 32732773 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction therapy on one arm
Number of subjects: 19
Study 32732773 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy on the other arm
Number of subjects: 19
Study 33858976 — intervention group
Group type: COMPARATOR
Intervention: Denosumab Q3M (P/Q3M)
Number of subjects: 0
Study 33858976 — intervention group
Group type: COMPARATOR
Intervention: Denosumab Q6M (P/Q6M)
Number of subjects: 0
Study 33858976 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab Q3M (Q3M/Q3M)
Number of subjects: 0
Study 33858976 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab Q6M (Q6M/Q6M)
Number of subjects: 0
Study 35640922 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2204
Study 35640922 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 2204
Study 34443991 — intervention group
Group type: EXPERIMENTAL
Intervention: LOVED program (n = 24)
Number of subjects: 24
Study 32589648 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg bid for eight weeks
Number of subjects: 39
Study 32589648 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of rifampicin, isoniazid, pyrazinamide and ethambutol
Number of subjects: 39
Study 35599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training group (bicycle ergometer rehabilitation training + conventional rehabilitation)
Number of subjects: 40
Study 35599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training group
Number of subjects: 40
Study 35599420 — intervention group
Group type: COMPARATOR
Intervention: Conventional training group
Number of subjects: 40
Study 33774144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 78
Study 33774144 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross Motor Abilities (GMA)
Number of subjects: 78
Study 33774144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (COG)
Number of subjects: 78
Study 33302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin + nitroglycerin
Number of subjects: 526
Study 33302662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 33302662 — intervention group
Group type: COMPARATOR
Intervention: PSP
Number of subjects: 526
Study 34984822 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitor (empagliflozin)
Number of subjects: 48
Study 33492703 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 8
Study 33492703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 32965602 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar ABP 798
Number of subjects: 0